Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:809291.
doi: 10.1155/2012/809291. Epub 2011 Oct 15.

Metabolic syndrome and triple-negative breast cancer: a new paradigm

Andrew A Davis  1 , Virginia G Kaklamani
Affiliations

Metabolic syndrome and triple-negative breast cancer: a new paradigm

Andrew A Davis et al. Int J Breast Cancer. 2012.

Abstract

Triple-negative breast cancers (TNBCs) are aggressive tumors with poor prognosis compared to other breast cancer subtypes. The evidence linking TNBC with the metabolic syndrome, which consists of central obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, and hypertension, has emerged from clinical studies and experiments using cell lines and mouse models. Epidemiological studies have associated abdominal obesity with increased incidence of TNBC. Additionally, insulin resistance, dyslipidemia, and hypertension are associated with increased incidence of breast cancer across all subtypes. The insulin-leptin-adiponectin axis has been implicated mechanistically in breast cancer tumorigenesis. Specifically, increased leptin and decreased adiponectin levels disrupt homeostatic signaling pathways involved in cell proliferation, survival, cell-cycle regulation, and angiogenesis. Insulin, insulin-like growth factor I (IGF-I), and epidermal growth factor receptor (EGFR) may mediate interactions between these two hormones. Further research will facilitate the development of targeted therapeutics and programs to modify lifestyle factors to modulate the insulin-leptin-adiponectin axis for TNBC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The insulin-leptin-adiponectin axis and risk of TNBC. Schematic representation demonstrates interactions of components in blood. After the compounds enter a normal breast cell, changes in proliferation, survival, cell-cycle regulation, and angiogenesis result in tumorigenesis of either TNBC or non-TNBC. Potential interventions for TNBC, at different levels, are included on the right.
See this image and copyright information in PMC

References

    1. Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. Journal of Surgical Oncology. 2008;97(1):30–34. - PubMed
    1. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the “triple- negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Research and Treatment. 2009;116(2):317–328. - PubMed
    1. Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research. 2008;14(5):1368–1376. - PubMed
    1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109(9):1721–1728. - PubMed
    1. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer. 2007;110(4):876–884. - PubMed